Selective inhibition of cancer cell self-renewal through a Quisinostat-histone H1.0 axis

Cristina Morales Torres, Mary Y. Wu, Sebastijan Hobor, Elanor N. Wainwright, Matthew J. Martin, Harshil Patel, William Grey, Eva Grönroos, Steven Howell, Joana Carvalho, Ambrosius P. Snijders, Michael Bustin, Dominique Bonnet, Paul D. Smith, Charles Swanton, Michael Howell and Paola Scaffidi ()
Additional contact information
Cristina Morales Torres: Francis Crick Institute
Mary Y. Wu: Francis Crick Institute
Sebastijan Hobor: Francis Crick Institute
Elanor N. Wainwright: Francis Crick Institute
Matthew J. Martin: Oncology R&D, AstraZeneca
Harshil Patel: Francis Crick Institute
William Grey: Francis Crick Institute
Eva Grönroos: Francis Crick Institute
Steven Howell: Proteomics, Francis Crick Institute
Joana Carvalho: Francis Crick Institute
Ambrosius P. Snijders: Proteomics, Francis Crick Institute
Michael Bustin: National Cancer Institute, National Institutes of Health
Dominique Bonnet: Francis Crick Institute
Paul D. Smith: Oncology R&D, AstraZeneca
Charles Swanton: Francis Crick Institute
Michael Howell: Francis Crick Institute
Paola Scaffidi: Francis Crick Institute

Nature Communications, 2020, vol. 11, issue 1, 1-15

Abstract: Abstract Continuous cancer growth is driven by subsets of self-renewing malignant cells. Targeting of uncontrolled self-renewal through inhibition of stem cell-related signaling pathways has proven challenging. Here, we show that cancer cells can be selectively deprived of self-renewal ability by interfering with their epigenetic state. Re-expression of histone H1.0, a tumor-suppressive factor that inhibits cancer cell self-renewal in many cancer types, can be broadly induced by the clinically well-tolerated compound Quisinostat. Through H1.0, Quisinostat inhibits cancer cell self-renewal and halts tumor maintenance without affecting normal stem cell function. Quisinostat also hinders expansion of cells surviving targeted therapy, independently of the cancer types and the resistance mechanism, and inhibits disease relapse in mouse models of lung cancer. Our results identify H1.0 as a major mediator of Quisinostat’s antitumor effect and suggest that sequential administration of targeted therapy and Quisinostat may be a broadly applicable strategy to induce a prolonged response in patients.

Date: 2020
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-020-15615-z Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-15615-z

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-020-15615-z

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().